Therapeutic Areas

TREM-1 is an amplifier of innate immune response. Its activation is mediated following infection with different types of pathogens, as well as following non-infectious tissue damage. The TREM-1 receptor triggers dysregulation of immune response, regardless of the type of pathogen or tissue damaged.

Septic shock

Inotrem is developing a therapeutic solution based on nangibotide for septic shock patients. The pathophysiology of septic shock is characterized by an excessive systemic inflammatory reaction in response to a serious infection. Its consequences include the dysfunction of vital organs and major hemodynamic disorders that may prove fatal for patients. Activation of the TREM-1 pathway is recognized as a key factor contributing to septic shock.

Covid-19

Actively engaged to fight the worldwide COVID-19 pandemic, Inotrem is also working on a treatment for patients in Intensive Care Units (ICUs) suffering from severe forms of COVID-19. This therapeutic program was declared “National Priority Research” by the French government. As in septic shock, the severe forms of COVID-19 are characterized by the dysregulated inflammatory reaction responsible for the respiratory distress that lead many patients to the critical care unit.  In that setting as well, the TREM-1 pathway is recognized as a key contributing factor to the severity of the disease.

Acute inflammation caused by severe tissue injury

Beyond severe infections, the TREM-1 pathway is also engaged when there is a severe tissue injury that induces a massive release of danger signals. Inotrem research group as well as independent academic works have confirmed that TREM-1 engagement promotes a dysregulated response that has the potential to worsen the severity of the initial insult in clinical situations such as ischemia/reperfusion after myocardial infarction, poly-traumatism, and stroke. Ischemia-reperfusion injury post myocardial infarction will be the first non-infectious conditions to be tested with nangibotide H1 2022.